Drug Profile
Research programme: protein kinase inhibitors - Cancer Therapeutics
Alternative Names: FAK inhibitors - Cancer Therapeutics; Focal adhesion kinase inhibitors - Cancer TherapeuticsLatest Information Update: 03 Jun 2022
Price :
$50
*
At a glance
- Originator Cancer Therapeutics CRC; Cytopia Limited
- Developer Amplia Therapeutics Limited; Cancer Therapeutics CRC
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Pulmonary fibrosis
Most Recent Events
- 03 Jun 2022 Preclinical development in Cancer is ongoing in Australia (Amplia Therapeutics pipeline, June 2022)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Australia
- 11 Mar 2019 Preclinical trials in Pulmonary fibrosis in Australia (unspecified route), before March 2019